Yes, tucatinib is FDA approved. It was approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of HER2-positive metastatic breast cancer and HER2-positive metastatic colorectal cancer.
Yes, tucatinib is FDA approved. It was approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of HER2-positive metastatic breast cancer and HER2-positive metastatic colorectal cancer.
